Crohn's disease and ulcerative colitis are disorders of unknown aetiology. Immunological mechanisms have been considered to be of major significance in their aetiology and pathogenesis, but conclusive evidence is lacking. One aspect of immunity, nonspecific immune competence, has been studied by several groups with conflicting results.
In general, studies in ulcerative colitis patients have not revealed a depression of immune competence (Hinz, Perlmann, and Hammarstrom, 1967; Parent, Barrett, and Wilson, 1971) . In contrast, patients with Crohn's disease have shown a high incidence of negative Mantoux responses (Blackburn, Hadfield, and Hunt, ,1939; Phear, 1958; Williams, 1965) , as well as diminished cutaneous delayed hypersensitivity reactions to dinitrochlorobenzene (Jones, Housley, Ashurst, and Hawkins, 1969) . Also the lymphocytes of patients with Crohn's disease have shown low responses to nonspecific mitogens such as phytohaemagglutinin (Walker and Greaves, 1969; Brown, Taub, Present, and Janowitz, 1970; Parent et al, 1971) . However, Received for publication 15 January 1974. other groups have found the lymphocyte response to mitogens to be normal (McHattie, Magil, Jeejeebbhoy, and Falk, 1971; Aas, Huizenga, Newcomer, and Shorter, 1972;  Asquith, Kraft, and Rothberg, 1973) and the Mantoux reaction in Crohn's patients to be unimpaired (Fletcher and Hinton, 1967; Geffroy, Colin, Hecketsweiler, and Segrestin, 1971) .
There are several possible reasons for these conflicting reports. The clinical status of patients with Crohn's disease fluctuates widely with exacerbations and remissions, and these changes in degree of illness may non-specifically affect immune status. The treatment of some patients with steroids or other anti-inflammatory medication may modify the immune response. Controls for the immunological testing have usually been healthy volunteers rather than patients with a comparable degree of illness. Also, most groups have used a single test of immune competence.
In an effort to resolve these conflicting results, we have performed a spectrum of tests of immune function in each patient, namely, peripheral blood lymphocyte count, serum immunoglobulin levels 
DNCB response
The DNCB sensitization and challenge were performed essentially as described by Aisenberg (1962) but using a lower sensitizing dose. In brief, 2000 ,ug DNCB in 0 1 ml acetone was applied within a plastic ring of 2.2 cm diameter to the front of the upper arm. At the same time 100 ,ug DNCB in 0.1 ml acetone was applied similarly to the volar surface of the forearm to detect prior sensitization. These sites were allowed to dry and were occluded by a dressing for 48 hours. Challenge doses of 50 ,ug and 100 gg DNCB were applied to the forearm 12-14 days later and the sites occluded for 24 hours. Responses were read at 72 hours, a positive response comprising induration and erythema at the test site.
STATISTICAL METHODS
Analysis of lymphocyte counts and immunoglobulin levels was carried out using t tests. Lymphocyte responses to PHA were assessed using t tests on log values. The Mantoux responses were evaluated by t tests on grades of response and Mann-Whitney tests to corroborate these. DNCB reactions were analysed using the Mann-Whitney test.
Results

INITIAL TESTS
Lymphocyte count There was no significant variation between Crohn's disease, colitis, and control patients overall or in relation to degree of illness or steroid therapy. Mean lymphocyte counts of the patient groups are shown in table III.
Serum immunoglobulin levels (table III) No overall differences in IgG levels were found between Crohn's disease, colitis, and control patients. However, IgG levels in steroid-treated 'well' Crohn's disease patients were significantly lower than in non-steroid treated 'well' Crohn's patients (p < 0-02) and also lower than in steroidtreated 'ill' Crohn's patients (p < 0.02).
Comparing the groups as a whole, IgA levels were significantly greater in Crohn's disease patients than in colitis patients (p < 0-005) or controls (p < 0.05). Values in colitis and control groups were not significantly different.
Among 'ill' patients of both steroid-and nonsteroid-treated groups, serum IgA levels were significantly higher in Crohn's disease than in ulcerative colitis (p < 0.02) but this difference was not seen in the 'well' groups of patients.
In steroid-treated Crohn's patients, IgA levels were very significantly higher in the 'ill' than in the In some of the patients early in the series the lymphocyte response to PHA was assessed morphologically by examination of stained smears. The numbers assessed in this way were insufficient for meaningful analysis and these results are omitted from the series.
Mantoux test (table IV) The Mantoux reaction showed no significant variation with disease group or degree of illness. Steroids were associated with depression of the reaction in Crohn's patients which was significant (p < 0.04) in the 'ill' group. This depressive effect of steroids was not significant in the small group of 'ill' colitis patients, although intensity ofresponse was diminish- Both 'ill' Crohn's and 'ill' control groups showed an increase in serum IgM levels following surgery (p < 0-005 Crohn's, P < 0.05 controls).
Considering the Mantoux and DNCB responses, four 'ill' control patients who were DNCB negative preoperatively became positive with improvement in their health following surgery. There was a general tendency to stronger reactions on repeated testing although one weak DNCB-positive response in a 'well' control patient became negative after surgery. In the 'ill' Crohn's patients, DNCB and Mantoux responses fluctuated with the clinical state of the patient and the dosage of steroids. Four patients became DNCB positive with the improvement in their general health following surgery, accompanied by reducing or discontinuing steroids. Three other patients became DNCB negative when ill and on steroids but reverted to positive with remission and stopping of steroids. Similar variations occurred in the Mantoux reaction related to changes in general health and/or steroid dosage.
Discussion
None of the five parameters tested differed significantly between ulcerative colitis and control patients, regardless of degree of illness or steroid therapy. Thus, according to our data, the immune competence of ulcerative colitis patients is normal.
In the Crohn's patients, lymphocyte counts were similar to those of controls. Our findings differ from those of Strober, Wochner, Carbone, and Waldmann (1967) who demonstrated significant lymphocytopenia in seven patients with Crohn's disease.
Serum IgA levels were elevated in patients with Crohn's disease. This finding has been previously reported (Deodhar, Michener, and Farmer, 1969) and is probably due to increased local IgA production in the bowel wall, either as a non-specific response to the inflammatory process or as a result of greater antigenic access through ulcerated mucosa. The higher levels in the 'ill' Crohn's patients are consistent with either concept. The normal serum IgA The rise in serum IgM after resection has been previously recorded (Gelernt, Present, and Janowitz, 1972 
